Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Liposomal Glutathione delivers 100 mg of reduced glutathione in a lemon-peppermint flavour per 2-pump serving
Special Population Considerations Population pharmacokinetic analyses revealed: Body weight influences GLP2 exposure (approximately 1.1% change per kg) Renal impairment (including end-stage renal disease) does not significantly impact pharmacokinetics Hepatic impairment (mild to severe) does not require dose adjustments Age, sex, race, and ethnicity do not have clinically relevant effects on GLP2 pharmacokinetics Study Populations GLP2 clinical research has included the following participant groups: Adults with type 2 diabetes Primary focus of SURPASS trials (over 6,000 participants) Adults with obesity or overweight SURMOUNT trials for chronic weight management Participants with metabolic comorbidities Including metabolic syndrome, prediabetes Heart failure patients with HFpEF and obesity SUMMIT trial population Adults with obstructive sleep apnea and obesity SURMOUNT-OSA studies Various demographic populations Multinational studies across diverse racial and ethnic groups Research Limitations & Regulatory Status Critical Gaps in Current Evidence Despite an extensive clinical development program, important limitations remain in the GLP2 evidence base
It has randomized Phase 3 human data in adults with HIV-associated lipodystrophy, where daily tesamorelin reduced visceral abdominal fat
Essential role for protein kinase C in oleic acid-induced glucagon-like peptide-1 secretion in vivo in the rat
Metabolic marker improvements
A secondary analysis of clinical trial data found that up to 40% of weight lost on semaglutide can be lean mass -- muscle and bone -- rather than fat, particularly in women and older adults
